| Name | CAS | MF | MW | Single-letter sequence | Three-letter sequence | Number of AA | Type | Inquiry |
|---|---|---|---|---|---|---|---|---|
| HSTP1 | C36H59N15O14S2 | 990.08 | H₂N–CDGRPDRAC–OH | H₂N–Cys–Asp–Gly–Arg–Pro–Asp–Arg–Ala–Cys–OH | 9 | aHSC-targeting peptide | ||
| TPLSYLKGLVTVG | C63H106N14O18 | 1347.6 | H2N–TPLSYLKGLVTVG–OH | H2N–Thr–Pro–Leu–Ser–Tyr–Leu–Lys–Gly–Leu–Val–Thr–Val–Gly–OH | 13 | TRAP–targeting peptide | ||
| FP16 | C44H73N13O9 | 928.13 | H2N–VLWLKNR–OH | H2N–Val–Leu–Trp–Leu–Lys–Asn–Arg–OH | 7 | FGF3-targeting peptide | ||
| CLT1 | C46H81N13O15S2 | 1120.34 | H2N–CGLIIQKNEC–OH | H2N–Cys–Gly–Leu–Ile–Ile–Gln–Lys–Asn–Glu–Cys–OH | 10 | Fibrin–fibronectin complex–targeting peptide | ||
| CLT2 | C36H61N13O17S2 | 1012.08 | H2N–CNAGESSKNC–OH | H2N–Cys–Asn–Ala–Gly–Glu–Ser–Ser–Lys–Asn–Cys–OH | 10 | Fibrin–fibronectin complex–targeting peptide | ||
| SBP1peptide | 2416761-69-6 | C127H184N30O42 | 2801.32 | H2N–IEEQAKTFLDKFNHEAEDLFYQS–OH | H2N–Ile–Glu–Glu–Gln–Ala–Lys–Thr–Phe–Leu–Asp–Lys–Phe–Asn–His–Glu–Ala–Glu–Asp–Leu–Phe–Tyr–Gln–Ser–OH | 23 | ||
| NPGTCKD-KWIECLLNG | C77H121N21O24S2 | 1789.04 | H2N–NPGTCKDKWIECLLNG–OH | H2N–Asn–Pro–Gly–Thr–Cys–Lys–Asp–Lys–Trp–Ile–Glu–Cys–Leu–Leu–Asn–Gly–OH | 16 | TAG-72–targeting peptide | ||
| TNYL | C60H88N14O18 | 1293.42 | H2N–TNYLFSPNGPIA–OH | H2N–Thr–Asn–Tyr–Leu–Phe–Ser–Pro–Asn–Gly–Pro–Ile–Ala–OH | 12 | EphB receptor–targeting peptide | ||
| CLSYYPSYC | C50H65N9O15S2 | 1096.23 | H2N–CLSYYPSYC–OH | H2N–Cys–Leu–Ser–Tyr–Tyr–Pro–Ser–Tyr–Cys–OH | 9 | Phosphatidylserine (PS)–targeting peptide | ||
| P4 | C30H56N14O8 | 740.87 | H2N–GGKRPAR–OH | H2N–Gly–Gly–Lys–Arg–Pro–Ala–Arg–OH | 7 | NRP-1–targeting peptide | ||
| P7 | C37H70N16O8 | 867.07 | H2N–RIGRPLR–OH | H2N–Arg–Ile–Gly–Arg–Pro–Leu–Arg–OH | 7 | NRP-1–targeting peptide | ||
| CGFYWLRSC | C52H71N13O12S2 | 1134.34 | H2N–CGFYWLRSC–OH | H2N–Cys–Gly–Phe–Tyr–Trp–Leu–Arg–Ser–Cys–OH | 9 | NRP-1–targeting peptide | ||
| DTPA | C45H73N15O24S1 | 1240.21 | H2N–DSEGNSNLCSQS–OH | H2N–Asp–Ser–Glu–Gly–Asn–Ser–Asn–Leu–Cys–Ser–Gln–Ser–OH | 12 | CD166-targeting peptide | ||
| RPARPAR peptide | C34H62N16O8 | 822.97 | H2N–RPARPAR–OH | H2N–Arg–Pro–Ala–Arg–Pro–Ala–Arg–OH | 7 | NRP-1–targeting peptide | ||
| CaIX-P1 | C66H97N17O19 | 1432.58 | H2N–YNTNHVPLSPKY–OH | H2N–Tyr–Asn–Thr–Asn–His–Val–Pro–Leu–Ser–Pro–Lys–Tyr–OH | 12 | Human carbonic anhydrase IX–targeting peptide | ||
| SWELYYPLRANL | C73H106N18O18 | 1523.73 | H2N–SWELYYPLRANL–NH2 | H2N–Ser–Trp–Glu–Leu–Tyr–Tyr–Pro–Leu–Arg–Ala–Asn–Leu–NH2 | 12 | E- and N-cadherin binding antagonist | ||
| SWTLYTPSGQSK | C61H92N16O19 | 1353.48 | H2N–SWTLYTPSGQSK–NH2 | H2N–Ser–Trp–Thr–Leu–Tyr–Thr–Pro–Ser–Gly–Gln–Ser–Lys–NH2 | 12 | N-cadherin antagonist | ||
| AP8 | C35H51N9O10 | 757.83 | H2N–AGNWTPI–OH | H2N–Ala–Gly–Asn–Trp–Thr–Pro–Ile–OH | 7 | aFGF-targeting peptide | ||
| P12 | C30H48N10O10 | 708.76 | H2N–HSQAAVP–OH | H2N–His–Ser–Gln–Ala–Ala–Val–Pro–OH | 7 | FGF8b-targeting peptide | ||
| FRSFESCLAKSH | C62H94N18O18S1 | 1411.58 | H2N–FRSFESCLAKSH–OH | H2N–Phe–Arg–Ser–Phe–Glu–Ser–Cys–Leu–Ala–Lys–Ser–His–OH | 12 | Interleukin-10 (IL-10)–targeting peptide |
Targeting peptides are short amino acid sequences, typically 5-30 residues long, that can specifically recognize and bind to molecular targets such as cell-surface receptors, membrane proteins, or tissue-specific markers. By selectively homing to these biological sites, they act as molecular "addresses" that direct drugs, imaging agents, or nanoparticles precisely where they are needed in the body. In other words, targeting peptides serve as biological guidance systems—they ensure that therapeutic or diagnostic agents reach the intended destination while minimizing off-target exposure. This makes them vital tools in precision medicine, nanotechnology, and molecular imaging.
It's important to distinguish targeting peptides from targeted peptides.
Designing effective targeting peptides involves careful optimization of sequence length, charge, hydrophobicity, and secondary structure to achieve high affinity, stability, and selectivity. Advanced approaches, such as phage display, computational design, and AI-driven peptide modeling, now accelerate this discovery process. In summary, targeting peptides are the building blocks of modern precision delivery systems-compact, versatile, and tunable molecules that bridge chemistry and biology to achieve specific therapeutic goals.
Traditional drug delivery methods often suffer from poor selectivity, meaning that only a fraction of the administered drug actually reaches the disease site. The rest may accumulate in healthy tissues, causing toxicity, off-target effects, and suboptimal bioavailability. This inefficiency is a major limitation in chemotherapy, gene therapy, and molecular imaging. Targeting peptides overcome these challenges by providing active biological guidance. When attached to drugs, nanoparticles, or imaging probes, they enable these cargos to home in on their intended targets-such as cancer cells, inflamed tissues, or specific organs. This targeted delivery increases therapeutic efficacy, allows for lower dosages, and reduces systemic side effects.
Compared to antibodies or aptamers, targeting peptides offer several distinct advantages:
Because of these features, targeting peptides have become central to the design of next-generation drug delivery systems, tumor-homing therapeutics, and biocompatible imaging agents. Their ability to combine molecular precision with structural simplicity makes them a cornerstone of the evolving field of peptide-based nanomedicine.
The fundamental mechanism of targeting peptides lies in their ability to engage in specific receptor-ligand interactions on the surface of target cells or tissues. These interactions enable receptor-mediated targeting, a process where the peptide recognizes molecular markers that are overexpressed in diseased or specialized environments. Among the best-studied targets are:
These peptides exhibit diverse structural motifs—linear, cyclic, or constrained sequences—optimized for high-affinity binding while maintaining proteolytic stability. For instance, cyclic RGD analogs (e.g., cRGDfK) show enhanced binding to αvβ3 integrins and improved in vivo performance compared to their linear counterparts. Modern design strategies often involve sequence engineering to fine-tune binding affinity, selectivity, and pharmacokinetics. Modifications such as amino acid substitution, stereochemical inversion (L- to D-form), or cyclization can significantly increase receptor affinity or reduce enzymatic degradation. Through such rational optimization, targeting peptides evolve from simple recognition motifs into highly efficient, receptor-specific delivery agents for use in cancer therapy, neuropharmacology, and targeted imaging.
For targeting peptides to function effectively in biomedical applications, they are often conjugated to therapeutic or diagnostic cargos, forming multifunctional delivery systems. The conjugation strategy determines not only targeting efficiency but also circulation time, biostability, and release kinetics.
Peptides can be covalently linked to drugs, proteins, or imaging probes using linkers or spacer molecules. Techniques such as PEGylation (attachment of polyethylene glycol) are widely employed to extend half-life, minimize immune clearance, and improve solubility. Linker chemistry allows controlled release of the active compound at the target site, often triggered by enzymatic or pH-sensitive cleavage.
2. Fusion Peptides
By combining cell-penetrating peptides (CPPs) with targeting domains, researchers create dual-function fusion peptides that can both home to specific cells and facilitate intracellular delivery. For example, fusions of RGD or Angiopep-2 with TAT sequences enhance uptake into tumor or brain tissues. These modular designs maximize the efficiency of drug and gene transport.
3. Nanoparticle Surface Functionalization
Targeting peptides are also incorporated onto the surfaces of nanoparticles, liposomes, or polymeric carriers through chemical or physical adsorption. This approach endows nanocarriers with biological "GPS" functionality—directing them to tumors, inflamed tissues, or specific organs. Common examples include RGD-modified liposomes for cancer imaging and Angiopep-2-decorated nanoparticles for BBB penetration.
4. Pharmacokinetic and Stability Optimization
To enhance in vivo performance, peptide conjugates are further refined through:
These structural and chemical modifications transform simple peptides into robust, clinically relevant delivery modules, capable of achieving controlled biodistribution and superior therapeutic index.
The diversity of targeting peptides reflects the complexity of their biological roles and engineering strategies. Researchers categorize these peptides in multiple ways—by target site, mechanism of action, structural type, functional role, discovery method, and application domain.
Each classification highlights a different aspect of their design, behavior, or therapeutic value.
One of the most intuitive and widely used systems classifies targeting peptides according to the organ, tissue, or cell type they recognize. This organ-targeting approach focuses on how peptides home to specific biological environments through receptor-ligand interactions.
| Target Site / Organ | Representative Peptides | Primary Target / Receptor | Application Highlights |
|---|---|---|---|
| Tumor (Solid Cancers) | RGD, iRGD, NGR, F3 | Integrins (αvβ3, αvβ5), CD13, NRP-1 | Tumor-homing and penetrating peptides used for cancer drug delivery, photothermal therapy, and imaging. |
| Brain / CNS | Angiopep-2, RVG29, T7 | LRP1, Nicotinic acetylcholine receptor, Transferrin receptor | Facilitate drug or nanoparticle transport across the blood–brain barrier (BBB) for neurodegenerative and brain tumor treatment. |
| Liver | ASGPR-binding peptides, SP94 | Asialoglycoprotein receptor (ASGPR) | Target hepatocytes for siRNA/mRNA or nanoparticle-based delivery in metabolic and viral liver diseases. |
| Heart | CSTSMLKAC | Ischemic myocardium surface markers | Guide regenerative drugs or imaging agents to ischemic heart tissue for cardiac repair. |
| Lung | LTP1–LTP3, CGSPGWVRC | Pulmonary endothelium markers | Improve pulmonary drug retention and reduce systemic toxicity in respiratory therapies. |
| Immune Cells (Macrophages, Dendritic Cells, T Cells) | CRV, M2pep, CP7 | Scavenger receptors, CD206, or specific immune surface ligands | Deliver immunomodulators or imaging probes to immune cells in inflammation and immunotherapy. |
| Kidney | CLPVASC, CKGGRAKDC | Renal endothelium / megalin–cubilin complex | Enable targeted renal imaging and reduce nephrotoxicity of systemic drugs. |
| Gastrointestinal Tract | PepT1-binding peptides | Peptide transporter 1 (PepT1) | Enhance oral absorption and mucosal targeting for peptide or protein therapeutics. |
Another key classification is based on the biological mechanism by which peptides interact with cells or tissues.
| Mechanism | Description | Example Peptides |
|---|---|---|
| Receptor-binding peptides | Recognize specific receptors overexpressed on target cells. | RGD (integrins), NGR (CD13), Angiopep-2 (LRP1), T7 (transferrin receptor) |
| Cell-penetrating peptides (CPPs) | Facilitate cell entry via endocytosis or membrane translocation, often non-specific. | TAT, penetratin, R9 |
| Tumor-penetrating peptides (TPPs) | Bind receptors, then activate tissue penetration pathways (e.g., CendR motif → NRP-1). | iRGD (CendR sequence) |
| Stimuli-responsive peptides | Activate or change conformation under specific conditions (pH, enzyme, redox, temperature). | pH-low insertion peptide (pHLIP), MMP-cleavable linkers |
| Transporter-targeting peptides | Exploit endogenous transporters for BBB or intestinal absorption. | Angiopep-2, GLUT1-binding peptides |
The structural architecture of targeting peptides strongly influences their stability, affinity, and pharmacokinetic properties.
| Structural Class | Description | Example |
|---|---|---|
| Linear peptides | Simple sequences, flexible, easy to synthesize but less stable. | NGR, T7 |
| Cyclic peptides | Formed by head-to-tail or side-chain cyclization; increased stability and affinity. | RGD cyclic forms (cRGDfK), CendR |
| Stapled peptides | Contain hydrocarbon staples or chemical bridges to lock 伪-helices. | SAH-Ras inhibitors |
| Peptide conjugates | Covalently linked to drugs, imaging agents, or polymers. | PDCs, fluorescent peptide probes |
| Peptidomimetics / D-peptides | Incorporate non-natural amino acids for protease resistance. | D-amino acid analogs, 尾-peptides |
In therapeutic and diagnostic platforms, targeting peptides perform distinct functional roles depending on how they interact with their cargo or biological environment.
| Functional Role | Description | Example |
|---|---|---|
| Ligand / targeting moiety | Directs nanoparticles or drugs to target cells. | RGD, NGR, Angiopep-2 |
| Carrier / shuttle | Transports cargo across barriers (e.g., BBB, cell membrane). | TAT, penetratin, transportan |
| Activator / trigger | Activates internalization or payload release. | CendR motif, MMP-cleavable linkers |
| Signal / reporter | Used for imaging or biosensing. | Fluorescent peptide probes, radiolabeled peptides |
The origin of targeting peptides reveals how they were identified and optimized, from natural sources to advanced computational design.
| Discovery Approach | Description | Example |
|---|---|---|
| Phage display-derived | Selected via high-throughput library screening. | RGD, NGR, LTP |
| In vivo biopanning | Selected directly in animal models for organ specificity. | Brain/liver-homing peptides |
| Natural or endogenous peptides | Derived from natural proteins or ligands. | Angiopep-2 (from aprotinin), somatostatin analogs |
| Computational / AI-designed | Predicted by in silico modeling and ML screening. | De novo AI-designed tumor-homing peptides |
Finally, targeting peptides can be categorized by their application field-spanning therapeutic delivery, diagnostics, and molecular imaging.
| Application | Typical Targets | Example |
|---|---|---|
| Drug delivery | Tumor, liver, brain | iRGD, Angiopep-2 |
| Radiopharmaceuticals | SSTR2, PSMA | DOTATATE, PSMA-targeting peptides |
| Fluorescence imaging | Tumor, lymph nodes | BLZ-100 (chlorotoxin-ICG) |
| Gene therapy / nucleic acid delivery | siRNA, mRNA systems | RGD-modified liposomes |
| Vaccine adjuvants / immunotherapy | APCs, lymph nodes | CpG-peptide conjugates |
The development of effective targeting peptides relies on two complementary strategies: experimental screening and computational design. These approaches combine molecular biology and bioinformatics to identify peptide sequences with high receptor affinity, tissue selectivity, and structural stability—cornerstones of modern precision therapeutics.
Phage display libraries remain the most established platform for discovering novel targeting peptides. In this technique, billions of random peptide sequences are displayed on bacteriophage surfaces and screened against biological targets such as receptors, cell membranes, or tissues. Peptides with strong binding are enriched through iterative selection cycles and subsequently sequenced. This process has yielded numerous well-characterized ligands, including RGD and NGR, which are widely used in receptor-mediated targeting for tumor and angiogenesis applications.
Other display-based methods, including mRNA display, bacterial display, and yeast surface display, provide alternative routes for peptide identification. These systems allow peptides to be expressed in various biological environments, maintaining conformational stability and enabling selection under near-physiological conditions. mRNA display offers exceptionally large library diversity, while cell-based displays are advantageous for discovering functional peptides compatible with complex biological systems.
In vivo biopanning extends the screening process into living organisms, allowing for the direct identification of organ-selective peptides. After systemic administration of peptide or phage libraries, sequences that localize to specific organs—such as the brain, liver, or lung—are isolated and analyzed. This approach captures physiological binding interactions that cannot be replicated in vitro, leading to the discovery of tissue-homing peptides that can cross biological barriers like the blood-brain barrier (BBB) or selectively target tumor vasculature. Collectively, these high-throughput screening methods form the foundation of precision peptide discovery and targeted delivery research.
In parallel with experimental methods, computational design and artificial intelligence (AI) have become essential tools for predicting and optimizing peptide-target interactions. Through molecular modeling and machine learning, researchers can simulate how peptide sequences bind to receptors, estimate binding affinities, and predict structural conformations before synthesis. These predictive models accelerate discovery by narrowing vast chemical spaces to a small subset of high-potential candidates.
Advanced algorithms trained on peptide-protein interaction data can evaluate physicochemical properties, folding patterns, and energetic stability. Structural prediction techniques now make it possible to visualize receptor-peptide complexes in three dimensions, providing insight into critical binding residues. Additionally, generative AI models can design new peptide sequences de novo, optimizing them for desired characteristics such as protease resistance, membrane permeability, or target specificity. Together, these computational peptide modeling approaches transform peptide discovery from empirical screening into a rational, data-driven process that integrates biology, chemistry, and artificial intelligence.
The clinical relevance of targeting peptides continues to expand across therapeutic, diagnostic, and translational medicine. These versatile molecules have proven effective in improving drug selectivity, reducing systemic toxicity, and enabling molecular imaging at unparalleled precision. Below are the main categories that define their real-world impact.
Peptide-drug conjugates (PDCs) combine targeting peptides with therapeutic molecules via cleavable linkers, allowing receptor-specific binding and controlled drug release. Compared to antibodies, PDCs are smaller, easier to synthesize, and penetrate tissues more efficiently, improving therapeutic precision.
Functionalizing nanoparticles and liposomes with targeting peptides enhances delivery to tumors or specific organs. These peptide-decorated systems improve biodistribution and uptake of chemotherapeutics or nucleic acids, making them a core strategy in modern nanoparticle targeting peptide research.
Peptide-based vaccines employ immunogenic sequences linked to targeting motifs to improve antigen presentation and immune activation. They provide tunable, biocompatible solutions for infectious disease prevention and cancer immunotherapy.
Radiolabeled targeting peptides, such as 68Ga-DOTATATE and 177Lu-DOTATATE, are key peptide imaging agents used in PET and SPECT to visualize somatostatin receptor-positive tumors. These tracers enable both diagnosis and therapy through peptide receptor radionuclide therapy (PRRT).
Fluorescent peptide probes like tozuleristide (Tumor Paint) use tumor-homing peptides conjugated to near-infrared dyes for real-time surgical imaging. They allow precise visualization of tumor margins and improve intraoperative decision-making.
iRGD (certepetide/LSTA1) enhances tumor penetration by binding integrins and activating the CendR pathway, increasing intratumoral drug accumulation in multiple clinical trials.
Angiopep-2 (ANG1005) utilizes receptor-mediated transport across the blood-brain barrier, enabling chemotherapy delivery to brain metastases and gliomas.
177Lu-DOTATATE, a radiolabeled somatostatin analog, is the first FDA-approved peptide-based radiotherapeutic, proving the clinical success of peptide receptor radionuclide therapy.
Despite their versatility, targeting peptides face challenges related to proteolytic degradation, short plasma half-life, and rapid renal clearance. These issues can limit in vivo efficacy and therapeutic window. To improve peptide stability and circulation time, several engineering strategies are employed: cyclization to restrict conformational flexibility, PEGylation to reduce enzymatic access and immune recognition, and incorporation of unnatural amino acids to enhance metabolic resistance. Such modifications extend peptide half-life without compromising target affinity, enabling more durable and effective therapeutic performance.
Large-scale peptide manufacturing requires stringent quality control to meet Good Manufacturing Practice (GMP) standards. Challenges include sequence-dependent synthesis complexity, purification of long or hydrophobic peptides, and cost-effective scale-up for clinical use. Advances in solid-phase peptide synthesis (SPPS) and automated purification have improved yield and consistency, but maintaining reproducibility across production batches remains essential. Regulatory oversight for peptide conjugates and radiolabeled peptides focuses on ensuring stability, purity, and safety, as these hybrid molecules combine biologic and small-molecule characteristics. Clearer regulatory pathways are now emerging to support commercialization of complex peptide therapeutics.
The future of peptide therapeutics lies in their integration with next-generation biotechnologies and computational innovation. Hybrid systems combining peptides with nucleic acid therapeutics—including mRNA, siRNA, and DNA nanostructures—offer precise control over delivery, targeting, and gene regulation. The synergy between AI-driven peptide discovery and structural modeling is accelerating the design of personalized, high-affinity ligands tailored to specific disease profiles. In addition, the emergence of dual-function peptides that combine targeting and cell-penetrating capabilities represents a major leap toward intelligent, self-guided therapeutics. These advancements position peptides at the forefront of precision medicine, where rational design meets adaptive biological function.
Targeting peptides are short amino acid sequences that specifically bind to receptors or biomarkers on certain cells or organs. They are used to guide drugs, nanoparticles, or imaging agents directly to disease sites, improving precision and reducing side effects.
Targeting peptides attach to receptors on target cells, triggering receptor-mediated uptake or selective accumulation of therapeutic agents. This peptide-guided delivery enhances treatment efficacy, minimizes off-target toxicity, and is widely applied in cancer therapy and nanomedicine.
Unlike large antibodies, targeting peptides are smaller, more stable, and easier to synthesize. They penetrate tissues more effectively, exhibit lower immunogenicity, and are cost-efficient to produce at scale—making them ideal for targeted drug delivery and molecular imaging.
The future of targeting peptides lies in their integration with nucleic acid therapies (mRNA, siRNA) and AI-driven design for personalized medicine. Dual-function peptides that combine targeting and cell penetration are emerging as key tools in precision medicine peptides and next-generation therapeutics.
The field of targeting peptides is transforming the future of precision medicine, drug delivery, and molecular imaging. These versatile molecules enable targeted, efficient, and customizable solutions that bridge biology and biotechnology for next-generation therapies and diagnostics.
If you are exploring targeting peptide technologies, seeking custom synthesis, or looking for innovative peptide-based solutions, our team is ready to collaborate. We provide advanced expertise and reliable support to help you accelerate development from concept to application.
Contact us today to discover how precision medicine peptides can elevate your research, product design, or therapeutic strategy.
